Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

The primary measure of ILD progression was a decline in forced vital capacity (FVC) of 5% or more between annual visits.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

Christina McKay, 36, learned that her husband, Duane, 40, would need a double lung transplant. But instead of succumbing to ...

Fibroblasts reprogrammed into AT2-like lung cells in just 7–10 days, offering a faster, safer alternative to stem cell ...

Japanese researchers have generated lung cells directly from mouse tissue. These lung cells are called Alveolar Epithelial ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...